Piper Sandler analyst Edward Tenthoff downgraded Jounce Therapeutics to Neutral from Overweight after Concentra Biosciences agreed to acquire Jounce for $1.85 in cash per share plus a non-tradeable contingent value right.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on JNCE:
- Buyout Offer Sends Jounce Jumping 20%
- Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights
- Jounce Therapeutics implements workforce reduction of 84% of employees
- Jounce to be acquired by Concentra for $1.85 in cash per share plus CVR
- Jounce: Patients from ovarian cancer combo cohort study had durable responses
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue